AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion.

The AML1-ETO fusion protein, generated by the t(8;21) in acute myeloid leukemia (AML), exerts dominant-negative functions and a variety of gains of function, including a positive effect on the growth of primary human CD34+ hematopoietic stem/progenitor cells. We now show that AML1-ETO expression up-regulates the level of TRKA mRNA and protein in these cells and that AML1-ETO-expressing CD34+ hematopoietic cells grown in the presence of five early-acting hematopoietic cytokines further proliferate in response to nerve growth factor (NGF). These cells also show a unique response to NGF and IL-3; namely, they expand in liquid culture. To determine the biological relevance of our findings, we analyzed 262 primary AML patient samples using real-time RT-PCR and found that t(8;21)-positive AML samples express significantly higher levels of TRKA mRNA than other subtypes of AML. NGF, which is normally expressed by bone marrow stromal cells, could provide important proliferative or survival signals to AML1-ETO-expressing leukemic or preleukemic cells, and the NGF/TRKA signaling pathway may be a suitable target for therapeutic approaches to AML.

[1]  Natalia Meani,et al.  Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. , 2003, The Journal of clinical investigation.

[2]  R. Bronson,et al.  Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Downing,et al.  AML1, the Target of Multiple Chromosomal Translocations in Human Leukemia, Is Essential for Normal Fetal Liver Hematopoiesis , 1996, Cell.

[4]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[5]  A. Jakubowiak,et al.  The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1 , 1999, Oncogene.

[6]  P. Boccuni,et al.  Transcription factor fusions in acute leukemia: variations on a theme , 2002, Oncogene.

[7]  M. Marín‐Padilla,et al.  Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. Tomasson,et al.  An activated receptor tyrosine kinase, TEL/PDGFβR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Licht,et al.  The ETO Protein Disrupted in t(8;21)-Associated Acute Myeloid Leukemia Is a Corepressor for the Promyelocytic Leukemia Zinc Finger Protein , 2000, Molecular and Cellular Biology.

[10]  J. Downing,et al.  Alterations of the AML1 transcription factor in human leukemia. , 2000, Seminars in cell & developmental biology.

[11]  John M. Maris,et al.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia , 1999, Nature Genetics.

[12]  E. Macintyre,et al.  High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. , 2000, Blood.

[13]  K. Tanaka,et al.  Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). , 1999, Blood.

[14]  T. Kyo,et al.  High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. , 2004, Blood.

[15]  P. Pandolfi,et al.  The t(8;21) fusion protein, AML1–ETO, specifically represses the transcription of the p14ARF tumor suppressor in acute myeloid leukemia , 2002, Nature Medicine.

[16]  S. Nakamura,et al.  Analysis of genes under the downstream control of the t(8;21) fusion protein AML1-MTG8: overexpression of the TIS11b (ERF-1, cMG1) gene induces myeloid cell proliferation in response to G-CSF. , 2000, Blood.

[17]  C. von Kalle,et al.  Murine Leukemia Induced by Retroviral Gene Marking , 2002, Science.

[18]  N. Speck.  Core binding factor and its role in normal hematopoietic development. , 2001, Current opinion in hematology.

[19]  M. Caligiuri,et al.  Identification and Characterization of an Activating TrkA Deletion Mutation in Acute Myeloid Leukemia , 2022 .

[20]  T. Hoshino,et al.  ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[21]  I. Weissman,et al.  AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  S. Jhanwar,et al.  Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. , 2003, Blood.

[23]  J. Downing,et al.  Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. , 2002, Cancer cell.

[24]  J. Rowley,et al.  Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Tenen,et al.  Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. , 2000, Blood.

[26]  D. Djakiew,et al.  Anti-proliferative effect of the kinase inhibitor K252a on human prostatic carcinoma cell lines. , 1996, Journal of andrology.

[27]  B. Hempstead,et al.  Neurotrophins: novel mediators of angiogenesis. , 2003, Frontiers in bioscience : a journal and virtual library.

[28]  D. Gilliland,et al.  Signal transduction and transforming properties of the TEL–TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia , 2000, The EMBO journal.

[29]  C. Glass,et al.  ETO, a Target of t(8;21) in Acute Leukemia, Interacts with the N-CoR and mSin3 Corepressors , 1998, Molecular and Cellular Biology.

[30]  A. Warren,et al.  Hematopoietic Stem Cell Expansion and Distinct Myeloid Developmental Abnormalities in a Murine Model of the AML1-ETO Translocation , 2002, Molecular and Cellular Biology.

[31]  M. Ohki,et al.  The t(8;21) translocation in acute myeloid leukemia results in production of an AML1‐MTG8 fusion transcript. , 1993, The EMBO journal.

[32]  J. Downing,et al.  Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. , 1998, Blood.

[33]  C. Stocking,et al.  AML1-ETO Inhibits Maturation of Multiple Lymphohematopoietic Lineages and Induces Myeloblast Transformation in Synergy with ICSBP Deficiency , 2002, The Journal of experimental medicine.

[34]  F. Alt,et al.  The CBFβ Subunit Is Essential for CBFα2 (AML1) Function In Vivo , 1996, Cell.

[35]  J. Zhang,et al.  The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. , 1995, Oncogene.

[36]  Ping Ji,et al.  Translocation Products in Acute Myeloid Leukemia Activate the Wnt Signaling Pathway in Hematopoietic Cells , 2004, Molecular and Cellular Biology.

[37]  D. Littman,et al.  Differential Requirements for Runx Proteins in CD4 Repression and Epigenetic Silencing during T Lymphocyte Development , 2002, Cell.

[38]  S. Minucci,et al.  Aberrant Recruitment of the Nuclear Receptor Corepressor-Histone Deacetylase Complex by the Acute Myeloid Leukemia Fusion Partner ETO , 1998, Molecular and Cellular Biology.

[39]  K. MacKenzie,et al.  The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. , 2002, Blood.

[40]  T. Noda,et al.  Hematopoiesis in the fetal liver is impaired by targeted mutagenesis of a gene encoding a non-DNA binding subunit of the transcription factor, polyomavirus enhancer binding protein 2/core binding factor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R. Verhaak,et al.  Prognostically useful gene-expression profiles in acute myeloid leukemia. , 2004, The New England journal of medicine.

[42]  E. Seto,et al.  A Mechanism of Repression by Acute Myeloid Leukemia-1, the Target of Multiple Chromosomal Translocations in Acute Leukemia* , 2000, The Journal of Biological Chemistry.

[43]  N. Lenny,et al.  The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation , 1995, Molecular and cellular biology.

[44]  J. Rowley,et al.  Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. , 1993, Blood.

[45]  T. Inaba,et al.  Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. , 2003, Blood.

[46]  S. Chevalier,et al.  Expression and functionality of the trkA proto-oncogene product/NGF receptor in undifferentiated hematopoietic cells , 1994 .

[47]  S. Chevalier,et al.  Nerve growth factor is involved in the supportive effect by bone marrow--derived stromal cells of the factor-dependent human cell line UT-7. , 1996, Blood.

[48]  A. Viale,et al.  Induction of C/EBPalpha activity alters gene expression and differentiation of human CD34+ cells. , 2003, Blood.

[49]  H. Yamasaki,et al.  Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. , 1999, Blood.

[50]  J. Zhang,et al.  The AML1/ETO fusion protein activates transcription of BCL-2. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[51]  P Dubus,et al.  Expression of neurotrophins and their receptors in human bone marrow. , 1999, The American journal of pathology.